Vibecotamab is a Monoclonal Antibody owned by Xencor, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.
Vibecotamab(XmAb-14045) elicits anti-cancer activity. The therapeutic candidate is a T-cell dependent bi-specific antibody (TDB), which allow one arm to target B cell antigen CD123 while the other arm recruits T cells by binding to the CD3 of the T-cell receptor. T cells have a central role in cell-mediated immunity. The therapeutic candidate evokes immune system. The type I antibodies may trigger cell death via apoptosis. The type II antibodies trigger cell death via direct cell death.
The revenue for Vibecotamab is expected to reach a total of $627m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vibecotamab NPV Report.
Vibecotamab is originated and owned by Xencor.
Vibecotamab(XmAb-14045) is under development for the treatment of hematologic malignancies such as relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome and chronic myeloid leukemia. It is administered intravenously. It is an extended bi-specific monoclonal antibody which contains both tumor antigen binding domain CD123 and cytotoxic T-cell binding domain (CD3 binding domain). The drug candidate is developed based on XmAb antibody engineering technology (bi-specific technology).
Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.
The company reported revenues of (US Dollars) US$275.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$122.7 million in FY2020. The operating profit of the company was US$43 million in FY2021, compared to an operating loss of US$76.8 million in FY2020. The net profit of the company was US$82.6 million in FY2021, compared to a net loss of US$69.3 million in FY2020. The company reported revenues of US$27.3 million for the third quarter ended September 2022, a decrease of 9.5% over the previous quarter.
Quick View – Vibecotamab
|Highest Development Stage|